Laura Soverchia
Overview
Explore the profile of Laura Soverchia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuhn B, Cannella N, Chitre A, Nguyen K, Cohen K, Chen D, et al.
Mol Psychiatry
. 2025 Feb;
PMID: 40000848
The increased prevalence of opioid use disorder (OUD) makes it imperative to disentangle the biological mechanisms contributing to individual differences in OUD vulnerability. OUD shows strong heritability, however genetic variants...
2.
Cannella N, Lunerti V, Shen Q, Li H, Benvenuti F, Soverchia L, et al.
Neuropharmacology
. 2024 Jun;
257:110048.
PMID: 38901642
Maintenance therapy with buprenorphine and methadone is the gold standard pharmacological treatment for opioid use disorder (OUD). Despite these compounds demonstrating substantial efficacy, a significant number of patients do not...
3.
Kuhn B, Cannella N, Chitre A, Nguyen K, Cohen K, Chen D, et al.
bioRxiv
. 2024 May;
PMID: 38712202
The increased prevalence of opioid use disorder (OUD) makes it imperative to disentangle the biological mechanisms contributing to individual differences in OUD vulnerability. OUD shows strong heritability, however genetic variants...
4.
Cannella N, Tambalo S, Lunerti V, Scuppa G, de Vivo L, Abdulmalek S, et al.
bioRxiv
. 2024 Mar;
PMID: 38463974
In opioid use disorder (OUD) patients, a decrease in brain grey matter volume (GMV) has been reported. It is unclear whether this is the consequence of prolonged exposure to opioids...
5.
Cannella N, Tambalo S, Lunerti V, Scuppa G, de Vivo L, Abdulmalek S, et al.
Brain Behav Immun
. 2024 Mar;
118:210-220.
PMID: 38452987
In opioid use disorder (OUD) patients, a decrease in brain grey matter volume (GMV) has been reported. It is unclear whether this is the consequence of prolonged exposure to opioids...
6.
Tovar R, de Ceglia M, Ubaldi M, Rodriguez-Pozo M, Soverchia L, Cifani C, et al.
Nutrients
. 2023 Oct;
15(20).
PMID: 37892524
Acylethanolamides (NAEs) are bioactive lipids derived from diet fatty acids that modulate important homeostatic functions, including appetite, fatty acid synthesis, mitochondrial respiration, inflammation, and nociception. Among the naturally circulating NAEs,...
7.
Lunerti V, Shen Q, Li H, Benvenuti F, Soverchia L, Narendran R, et al.
bioRxiv
. 2023 Aug;
PMID: 37546836
The gold standard pharmacological treatment for opioid use disorder (OUD) consists of maintenance therapy with long-acting opioid agonists such as buprenorphine and methadone. Despite these compounds having demonstrated substantial efficacy,...
8.
Cannella N, Borruto A, Petrella M, Micioni Di Bonaventura M, Soverchia L, Cifani C, et al.
Pharmaceuticals (Basel)
. 2022 Jul;
15(7).
PMID: 35890099
The neuropeptide S (NPS) is the endogenous ligand of the NPS receptor (NPSR). The NPSR is widely expressed in brain regions that process emotional and affective behavior. NPS possesses a...
9.
Lunerti V, Li H, Benvenuti F, Shen Q, Domi A, Soverchia L, et al.
Eur J Pharmacol
. 2022 Jun;
928:175088.
PMID: 35690082
Tobacco use disorder is a worldwide health problem for which available medications show limited efficacy. Nicotine is the psychoactive component of tobacco responsible for its addictive liability. Similar to other...
10.
Ubaldi M, Cannella N, Borruto A, Petrella M, Micioni Di Bonaventura M, Soverchia L, et al.
Int J Mol Sci
. 2021 Dec;
22(23).
PMID: 34884757
Nociceptin/orphanin FQ (N/OFQ) is a 17-residue neuropeptide that binds the nociceptin opioid-like receptor (NOP). N/OFQ exhibits nucleotidic and aminoacidics sequence homology with the precursors of other opioid neuropeptides but it...